ftInvstr
AKUMS · Healthcare ₹763.85 -1.82% Mkt Cap ₹11696 Cr fair

AKUMS

Healthcare Drug Manufacturers - Specialty & Generic
₹763.85
-1.82% today · 30d +14.86%
as of 2026-09-04
Price · Daily Candles
“Akums navigates volatile profit landscape as FIIs re-enter, despite Q4 net profit dip.”
Akums, with a market cap of ₹8505 Cr, posted a 9.69% YoY revenue increase in Q4 2026, yet net profit plunged by 45.63% YoY to ₹81 Cr. Despite this, FIIs increased their stake by 0.22% QoQ to 1.37%, while DIIs trimmed theirs by 0.05%. The stock exhibits strong technicals with a 1-year return of -3.2% but a 6-month return of 33.02%.
BULL CASE
+Q4 2026 revenue increased by 9.69% YoY to ₹1158 Cr, indicating continued top-line growth.
+Operating profit for Q4 2026 saw a substantial increase of 67.8% YoY, reaching ₹187 Cr.
+The 3-year net profit CAGR stands at 39.3%, demonstrating historical profitability strength.
+Technical indicators MACD (1.7378) and RSI(14) (62.87) are bullish, suggesting positive short-term momentum.
+Strong promoter holding at 75.26% as of March 2026, providing stability.
BEAR CASE
Q4 2026 net profit declined significantly by 45.63% YoY to ₹81 Cr, despite revenue growth.
Annual net profit for FY 2026 decreased by 25.42% YoY to ₹256 Cr.
The stock has delivered a negative 1-year return of -3.2%.
ML model predicts 'weak' future cash flow growth, with FCF 1Y recent 2Y at 0.25 rank and FCF 1Y stable 7Y at 0.018 rank.
The company's ROCE at 15.0% is significantly lower than some sector peers like Dr. Reddy's (27.63%) and Zydus Life (25.71%).
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹1167 Cr
+13.93% YoY
NET PROFIT
₹101 Cr
+56.11% YoY
OPM
17.13%
+2.31pp YoY
EPS
₹6.53
PE 33.22
Intrinsic value · DCF ₹945.61 · Margin of safety +23.8% (fair) · FCF yield 8.13%
◇ Sector Position
Akums trades at a PE of 33.22 with a ROCE of 15.0%, positioning it below the peer average where CIPLA (PE 29.13, ROCE 25.09) and ZYDUSLIFE (PE 21.65, ROCE 25.71) offer more compelling valuations and returns.
PEERPEROCE %
AKUMS33.2215.0
SUNPHARMA39.0822.46
DIVISLAB68.1921.47
CIPLA29.1325.09
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
63
SCORE / 100
Overall
6-axis composite of the sections below.
Performance STRONG 100
Valuation FAIR 40
Growth MUTED 41
Profitability HIGH 78
Technicals STRONG 70
Risk MODERATE 50
Key Stats
TTM PE
33.22
P/B
2.56
52W HIGH
₹796.55
OFF HIGH
-4.11%
DIV YIELD
0.18%
MKT CAP
₹11696 Cr
◉ Active Signals
MACDNeutral-1.8119
RSI(14)Neutral58.36
Near 52W HighBullish-4.11
Street Consensus
3 analysts
₹690.0
mean target
Low ₹610.0Now ₹763.85High ₹780.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold AKUMS and at what entry.

Sign up freeSign in